Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Decline in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) experienced a notable decrease in short interest during December. By December 31st, the short interest for this stock was recorded at 1,030,000 shares, reflecting a 14.2% drop from the earlier count of 1,200,000 shares as of December 15th. Presently, 1.8% of Nautilus's total shares are short sold. Given the average daily trading volume of 131,000 shares, the current days-to-cover ratio stands at 7.9 days.

Recent Activity by Institutional Traders

Recent months have seen various hedge funds adjusting their stakes in Nautilus Biotechnology. SG Americas Securities LLC entered a new investment in the company during the third quarter, valued at about $50,000. Similarly, The Manufacturers Life Insurance Company acquired a fresh position totaling approximately $67,000. Additionally, China Universal Asset Management Co. Ltd. boosted its shares by 63.9% in the same period, now owning 24,121 shares worth about $69,000 after buying 9,404 additional shares. MetLife Investment Management LLC also initiated a new stake, approximating $87,000 in value. Barclays PLC increased its holdings by an impressive 79.6%, resulting in 106,174 shares valued at $303,000 following the purchase of another 47,059 shares. Presently, institutional investors hold 50.71% of the stock.

Market Analysis and Analyst Ratings

In a separate development, The Goldman Sachs Group recently downgraded Nautilus Biotechnology's stock from a "neutral" rating to a "sell" rating. They also revised the price target down from $2.25 to $1.75 in their research report circulated on December 5th.

Nautilus Biotechnology Stock Performance

On the trading day of Thursday, NASDAQ NAUT traded down by $0.04, reaching a value of $1.90. A total of 68,207 shares were exchanged during the day, which is lower than the average trading volume of 139,801 shares. The company now possesses a market cap of $238.56 million, with a P/E ratio of -3.39 and a beta of 1.20. Over the last year, the stock has fluctuated, with a low of $1.61 and a high of $3.12. The 50-day and 200-day simple moving averages are $2.05 and $2.43, respectively.

Nautilus Biotechnology last released its quarterly earnings on October 29th. The company reported a loss of ($0.13) per share for the quarter, which was better than the consensus estimate of ($0.17) by $0.04. The same quarter from the previous year also recorded a loss of ($0.13) per share. Analysts project that Nautilus will report an earnings per share of -0.57 for the current year.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc. is a life sciences company currently in the development stage. The firm is dedicated to creating advanced technology for the proteome, aiming to provide an end-to-end solution utilizing instruments, consumables, and software analysis.

Nautilus, Biotechnology, Stocks